The U.S. Drug Enforcement Administration (DEA) has opened a new registration process for state-licensed medical cannabis manufacturers, distributors and analytical laboratories seeking to operate under Schedule III of the Controlled Substances Act.
The DEA’s Diversion Control Division launched the new online application process on October 5. Eligible businesses can apply using DEA Form 225, which is used for manufacturers, distributors and certain other handlers of controlled substances.
The new process follows the federal government’s April decision to place certain state-licensed medical cannabis and FDA-approved marijuana products into Schedule III. Cannabis that does not fall within those categories, including adult-use marijuana, remains federally classified as a Schedule I substance.
New DEA Registration Process Opens for Medical Cannabis Businesses
The new Form 225 process is intended for medical cannabis businesses involved in activities including cultivation, production, processing, packaging, labeling and transferring cannabis.
Manufacturers can apply to conduct those activities, while distributors can seek registration to receive and transfer medical cannabis. Analytical laboratories can also apply for authorization to test covered cannabis products.
Businesses that already submitted a Form 225 application to handle Schedule III medical cannabis do not need to submit another application. The DEA has stated that it will contact those applicants to continue processing their registrations.
The new application process comes several months after the DEA opened a separate 60-day expedited registration period for medical cannabis dispensaries. That window closed June 26 and provided qualifying applicants with expedited review, with the DEA directed to make every effort to process applications within six months.
Although that expedited window has ended, medical cannabis businesses can still pursue DEA registration. The newer Form 225 process does not carry the same expedited-review deadline.
What Businesses Need to Provide
The online Form 225 application requires businesses to provide information about the company, its state cannabis licenses, the controlled substances it intends to handle, and the activities it plans to conduct.
Applicants must identify their state license number and expiration date and select the applicable Schedule III category. The application specifically asks whether the business will handle medical marijuana and whether it will handle recreational marijuana.
The application also includes a detailed background section. Businesses must disclose certain past controlled-substance convictions, federal or state registration issues and disciplinary actions involving professional licenses or controlled-substance registrations.
If an applicant answers yes to any of the applicable background questions, additional information about the event, including its date, location and outcome, must be provided.
Businesses must also identify the substances they expect to handle, which can include marijuana, marijuana extract and certain naturally derived delta-9 THC products covered by the federal order.
The DEA registration comes with an annual, nonrefundable fee. Current Form 225 fees are listed at $3,699 for medical cannabis manufacturers, $1,850 for distributors and $296 for analytical laboratories.
Schedule III Brings Potential Tax Benefits and Federal Oversight
The federal move to Schedule III has significant implications for qualifying medical cannabis businesses, particularly regarding Section 280E of the Internal Revenue Code.
Under 280E, businesses trafficking in Schedule I or II controlled substances generally cannot deduct ordinary business expenses such as payroll, rent and utilities. Moving qualifying medical cannabis to Schedule III removes that specific federal tax restriction for businesses covered by the change.
At the same time, the shift also brings qualifying medical cannabis businesses further into the federal controlled-substance regulatory system.
Congressional researchers have previously concluded that businesses handling covered medical cannabis need to register with the DEA to comply with the Controlled Substances Act. The DEA registration process therefore represents more than an administrative filing; it establishes a federal oversight relationship for businesses that have historically operated primarily under state cannabis regulations.
The federal government has said the registration framework is intended to help meet federal obligations under the Controlled Substances Act and international drug-control requirements while incorporating existing state cannabis licensing systems.
What This Means for Cannabis Businesses
The opening of the Form 225 portal gives qualifying medical cannabis manufacturers, distributors and laboratories another step toward participating in the federal Schedule III framework.
For businesses considering registration, the process also introduces new federal compliance requirements that should be carefully evaluated alongside existing state obligations. Applicants will need to review their licensing history, compliance records, business activities and documentation before submitting an application.
It is also important for businesses to understand the limits of the federal change. Schedule III treatment applies to qualifying medical cannabis and does not mean that all cannabis has been federally rescheduled. Adult-use cannabis remains subject to its existing federal classification.
As the DEA begins processing applications under the new system, medical cannabis businesses will have to determine how federal registration fits into their operations and long-term compliance strategy.
